Should I buy or sell 10x Genomics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares. View TXG analyst ratings or view top-rated stocks .

What is 10x Genomics' stock price target for 2024?

12 analysts have issued twelve-month target prices for 10x Genomics' stock. Their TXG share price targets range from $26.00 to $75.00. On average, they anticipate the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts .

How have TXG shares performed in 2024?

10x Genomics' stock was trading at $55.96 at the beginning of the year. Since then, TXG stock has decreased by 50.9% and is now trading at $27.48. View the best growth stocks for 2024 here .

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TXG earnings forecast .

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings results on Tuesday, April, 30th. The company reported ($0.50) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.50). The firm had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative trailing twelve-month return on equity of 30.85%. 10x Genomics's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) earnings per share.

What ETFs hold 10x Genomics' stock?

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Sprott Junior Gold Miners ETF (SGDJ) , ARK Genomic Revolution ETF (ARKG) , Sprott Gold Miners ETF (SGDM) , U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU) , Global X Genomics & Biotechnology ETF (GNOM) , Global X Gold Explorers ETF (GOEX) , ARK Innovation ETF (ARKK) and Tema Oncology ETF (CANC) .

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $677.8 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com . Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.23%), Sumitomo Mitsui Trust Holdings Inc. (3.04%), Nikko Asset Management Americas Inc. (3.04%), Mirae Asset Global Investments Co. Ltd. (0.27%), Assenagon Asset Management S.A. (0.05%) and Mirador Capital Partners LP (0.02%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson , Bradford Crutchfield , James Wilbur , John R Stuelpnagel, John R Stuelpnagel , Justin J Mcanear, Justin J Mcanear , Mathai Mammen , Serge Saxonov and Sridhar Kosaraju . View institutional ownership trends .

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

→ Gold Mania (From Stansberry Research) (Ad)

Free TXG Stock Alerts

$27.48

+1.19 (+4.53%)

(As of 05/3/2024 ET)

Compare

Today's Range: $26.98
▼
$27.92
50-Day Range: $26.29
▼
$47.16
52-Week Range: $24.60
▼
$63.57

Volume: 2.35 million shs
Average Volume: 1.56 million shs
Market Capitalization: $3.27 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.50

Get 10x Genomics alerts:

10x Genomics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.58 Rating Score
Upside/Downside: 76.5% Upside
$48.50 Price Target
Short Interest: Bearish
7.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: -0.21
Based on 36 Articles This Week
Insider Trading: Selling Shares
$592,806 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.47) to ($0.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.41 out of 5 stars

Medical Sector

685th out of 5,430 stocks

Analytical Instruments Industry

25th out of 168 stocks

4.3

Analyst's Opinion

Consensus Rating
10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
10x Genomics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
7.44% of the outstanding shares of 10x Genomics have been sold short.
Short Interest Ratio / Days to Cover
10x Genomics has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in 10x Genomics has recently increased by 4.11%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
10x Genomics does not currently pay a dividend.
Dividend Growth
10x Genomics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.
Environmental Sustainability
The Environmental Impact score for 10x Genomics is -0.73.

1.6

News and Social Media Coverage

News Sentiment
10x Genomics has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 36 news articles for 10x Genomics this week, compared to 4 articles on an average week.
Search Interest
Only 10 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.
MarketBeat Follows
9 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $592,806.00 in company stock.
Percentage Held by Insiders
10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for 10x Genomics are expected to grow in the coming year, from ($1.47) to ($0.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 10x Genomics is -12.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 10x Genomics is -12.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
10x Genomics has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

Elon to Transform U.S. Economy?

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.